Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus

Next Previous
X
Search
Trial Profile

Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alfacon-1 (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms REACH-SVR
  • Sponsors Kadmon Pharmaceuticals; Three Rivers Pharmaceuticals

    • Most Recent Events

    • 02 Sep 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 23 May 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top